Literature DB >> 32253276

Benefits of Continuing RAAS Inhibitors in Advanced CKD.

Marie-Michèle Gaudreault-Tremblay1, Bethany J Foster2.   

Abstract

Keywords:  ACE inhibitors; Angiotensin-Converting Enzyme Inhibitors; Chronic; Renal Insufficiency; Renin-Angiotensin System; chronic kidney disease; chronic kidney failure; chronic renal insufficiency; clinical nephrology; pediatric nephrology; progression of chronic renal failure; progression of renal failure; proteinuria; renal protection; renin angiotensin system

Mesh：

Substances：

Year:  2020        PMID： 32253276      PMCID： PMC7269212          DOI： 10.2215/CJN.02920320

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   8.237


× No keyword cloud information.
  10 in total

Review 1.  Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease.

Authors:  G F M Strippoli; C Bonifati; M Craig; S D Navaneethan; J C Craig
Journal:  Cochrane Database Syst Rev       Date:  2006-10-18

Review 2.  Revisiting RAAS blockade in CKD with newer potassium-binding drugs.

Authors:  Panagiotis I Georgianos; Rajiv Agarwal
Journal:  Kidney Int       Date:  2017-12-21       Impact factor: 10.612

3.  Discontinuation of RAAS Inhibition in Children with Advanced CKD.

Authors:  Sophie M van den Belt; Hiddo J L Heerspink; Marietta Kirchner; Valentina Gracchi; Daniela Thurn-Valsassina; Aysun K Bayazit; Anna Niemirska; Nur Canpolat; Ipek Kaplan Bulut; Karolis Azukaitis; Ali Duzova; Justine Bacchetta; Rukshana Shroff; Dusan Paripovic; Zeynep Birsin Özçakar; Kibriya Fidan; Hakan Erdogan; Jutta Gellermann; Elke Wühl; Dick de Zeeuw; Anette Melk; Uwe Querfeld; Franz Schaefer
Journal:  Clin J Am Soc Nephrol       Date:  2020-04-06       Impact factor: 8.237

4.  An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function.

Authors:  Frank A Holtkamp; Dick de Zeeuw; Merlin C Thomas; Mark E Cooper; Pieter A de Graeff; Hans J L Hillege; Hans-Henrik Parving; Barry M Brenner; Shahnaz Shahinfar; Hiddo J Lambers Heerspink
Journal:  Kidney Int       Date:  2011-03-30       Impact factor: 10.612

5.  Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?

Authors:  G L Bakris; M R Weir
Journal:  Arch Intern Med       Date:  2000-03-13

6.  Efficacy and safety of benazepril for advanced chronic renal insufficiency.

Authors:  Fan Fan Hou; Xun Zhang; Guo Hua Zhang; Di Xie; Ping Yan Chen; Wei Ru Zhang; Jian Ping Jiang; Min Liang; Guo Bao Wang; Zheng Rong Liu; Ren Wen Geng
Journal:  N Engl J Med       Date:  2006-01-12       Impact factor: 91.245

7.  The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease.

Authors:  Aimun K Ahmed; Neetha S Kamath; Mohsen El Kossi; A Meguid El Nahas
Journal:  Nephrol Dial Transplant       Date:  2009-10-10       Impact factor: 5.992

8.  Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group.

Authors:  G Maschio; D Alberti; G Janin; F Locatelli; J F Mann; M Motolese; C Ponticelli; E Ritz; P Zucchelli
Journal:  N Engl J Med       Date:  1996-04-11       Impact factor: 91.245

Review 9.  Use of Renin-Angiotensin System Blockade in Advanced CKD: An NKF-KDOQI Controversies Report.

Authors:  Matthew R Weir; Jay I Lakkis; Bernard Jaar; Michael V Rocco; Michael J Choi; Holly J Kramer; Elaine Ku
Journal:  Am J Kidney Dis       Date:  2018-09-07       Impact factor: 8.860

10.  Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial.

Authors:  Sunil Bhandari; Natalie Ives; Elizabeth A Brettell; Marie Valente; Paul Cockwell; Peter S Topham; John G Cleland; Arif Khwaja; Meguid El Nahas
Journal:  Nephrol Dial Transplant       Date:  2015-09-30       Impact factor: 5.992
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.